SCHEMBL801703

SCHEMBL801703

CC(C)c1ccc(-n2ccnc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.63
LMNA P02545 1/20 0.63
MAPT P10636 1/20 0.63
ENPP2 Q13822 1/20 0.58
MKNK1 Q9BUB5 1/20 0.58
MKNK2 Q9HBH9 1/20 0.58
CYP3A4 P08684 4/20 0.57
KMT2A Q03164 3/20 0.55
MEN1 O00255 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
BAZ2B Q9UIF8 1/20 0.54
TDP1 Q9NUW8 1/20 0.52
CYP19A1 P11511 2/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278915 0.85 LMNA (0.59) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL6895118 0.85 ENPP2 (0.59) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL8047855 0.85 LMNA (0.55) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL6892003 0.85 NOTUM (0.59) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL1846405 0.84 MAPT (0.55) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL2532397 0.83 LMNA (0.78) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL10311213 0.82 CYP3A4 (0.53) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL9364392 0.81 LMNA (0.50) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL14438346 0.81 TDP1 (0.56) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL27513744 0.81 CYP3A4 (0.51) NOTUMLMNAMAPTENPP2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239892-A1 COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF ARKUDA THERAPEUTICS (US) 2023-12-14 WO disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11697648-B2 Fused pyrimidine pyridinone compounds as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-07-11 US disclosed
US-11697648-B2 Fused pyrimidine pyridinone compounds as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-07-11 US disclosed
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS UNIV CALIFORNIA (US) 2023-05-11 US disclosed
US-20230128041-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-04-27 US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-20220380402-A1 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2022-12-01 US disclosed
US-11236082-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-01 US disclosed
WO-2021203016-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 WO disclosed
US-20100298359-A1 GAMMA SECRETASE MODULATORS MERCK SHARP & DOHME CORP. 2010-11-25 US disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD 2010-07-22 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
US-20080176815-A1 Compounds that interact with kinases ALCHEMIA LIMITED (AU) 2008-07-24 US disclosed
US-20080176815-A1 Compounds that interact with kinases ALCHEMIA LIMITED (AU) 2008-07-24 US disclosed
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use NITROMED, INC. (US) 2008-01-10 US disclosed
US-7291623-B2 Compounds that interact with kinases ALCHEMIA LIMITED (AU) 2007-11-06 US disclosed
US-7291623-B2 Compounds that interact with kinases ALCHEMIA LIMITED (AU) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298359-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 NOTUM 1318/4885LMNA 2080/4885MAPT 318/4885
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO NOTUM 348/4885LMNA 4767/4885MAPT 3488/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOTUM 4102/4885LMNA 816/4885MAPT 458/4885
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use PDE3A, PDE3B, PDE2A NOTUM 750/4885LMNA 3053/4885MAPT 4431/4885
US-20230128041-A1 PARP1 INHIBITORS AND USES THEREOF PARP1, PARP11, PARP12 NOTUM 3876/4885LMNA 316/4885MAPT 3390/4885
US-20080176815-A1 Compounds that interact with kinases MAP3K6, MAP3K20, MAP4K2 NOTUM 2151/4885LMNA 4382/4885MAPT 3962/4885
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 NOTUM 3541/4885LMNA 48/4885MAPT 3463/4885
US-11697648-B2 Fused pyrimidine pyridinone compounds as JAK inhibitors JAK3, JAK1, JAK2 NOTUM 4710/4885LMNA 4833/4885MAPT 3409/4885
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS HSPBP1, HSPA8, HSPH1 NOTUM 2452/4885LMNA 2827/4885MAPT 1086/4885
US-20220380402-A1 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY ADORA2A, ADORA1, ADORA3 NOTUM 4364/4885LMNA 3199/4885MAPT 4608/4885
US-11236082-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 NOTUM 2480/4885LMNA 2203/4885MAPT 3296/4885
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT SIRT6, LAS1L, MRPS18A NOTUM 2910/4885LMNA 99/4885MAPT 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.